2026 | Vol 2(7) | July
Good Clinical Practice
2026CURRENT ISSUE
Good Clinical Practice (GCP) is an internationally recognized ethical, scientific, and quality standard for designing, conducting, recording, monitoring, analyzing, and reporting clinical trials involving human participants. The International Council for Harmonisation (ICH) developed the ICH E6(R3) Guideline, adopted on 6 January 2025, to ensure that clinical trials protect the rights, safety, and well-being of participants while producing reliable and credible scientific data. The guideline provides a unified framework for regulatory authorities, sponsors, investigators, ethics committees, and other stakeholders involved in clinical research.
The ICH E6(R3) guideline builds upon earlier versions by introducing a more flexible, risk-based, and quality-focused approach to clinical trials. It recognizes that modern clinical research incorporates innovative trial designs, digital technologies, decentralized methods, and diverse healthcare settings. Instead of prescribing rigid procedures, the guideline emphasizes applying GCP principles proportionately according to the complexity, objectives, and risks of each clinical trial.
Purpose and Scope
The primary objective of GCP is to ensure that clinical trials are conducted ethically and scientifically, producing reliable evidence while safeguarding participants. The guideline applies primarily to interventional clinical trials involving investigational products intended for regulatory submissions, although its principles may also be useful for other clinical studies. It encourages sponsors and investigators to integrate quality into trial planning from the beginning rather than relying solely on inspections or corrective actions after problems occur.
The guideline also highlights that trial quality depends on identifying factors critical to quality and managing risks that may affect participant protection or data reliability. By adopting a risk-based approach, unnecessary procedures can be minimized, making clinical trials more efficient without compromising ethical or scientific standards.
Fundamental Principles of Good Clinical Practice
The ICH E6(R3) guideline establishes several overarching principles that guide every stage of a clinical trial.
Ethical Conduct
Clinical trials must be conducted according to ethical principles originating from the Declaration of Helsinki and applicable regulatory requirements. The rights, safety, and well-being of participants must always take precedence over the interests of science or society. Before initiating a trial, investigators and sponsors must carefully evaluate whether the anticipated benefits justify the potential risks. Clinical trials should continue only if this balance remains favorable throughout the study.
Participant confidentiality is another essential ethical obligation. Personal information should be protected according to applicable privacy and data protection laws, ensuring that identifiable participant information remains secure.
Informed Consent
Obtaining informed consent is one of the most important requirements of GCP. Participation in clinical research must always be voluntary. Participants should receive clear, understandable information regarding the purpose of the study, procedures involved, potential benefits, possible risks, and available alternatives before agreeing to participate.
The informed consent process should be designed to help participants make well-informed decisions rather than simply obtaining signatures. For participants unable to provide consent themselves, legally authorized representatives may consent on their behalf according to local regulations. When minors participate in clinical trials, appropriate assent should also be obtained whenever applicable.
The guideline also addresses emergency research situations where prior consent may not be possible. In such cases, consent should be obtained as soon as possible following applicable regulatory and ethics committee requirements.
Independent Ethical Review
Every clinical trial must undergo review and approval by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before enrollment begins. These independent bodies evaluate whether participant rights, safety, and welfare are adequately protected and whether the proposed research is ethically acceptable.
Ethics committees should continue reviewing the trial periodically throughout its duration, particularly when important safety information or protocol amendments arise.
Scientific Soundness
Clinical trials must be scientifically justified and based on adequate preclinical and clinical evidence. The available scientific knowledge should support the proposed investigation, including understanding of the investigational product, disease condition, and target population.
The guideline emphasizes that scientific knowledge evolves continuously. Therefore, sponsors and investigators should periodically review emerging evidence during the trial and modify the study when necessary to maintain participant safety and scientific validity.
Qualified Personnel
Clinical trials should be conducted by individuals with appropriate education, training, and experience. Different experts—including physicians, nurses, pharmacists, statisticians, scientists, trial coordinators, monitors, auditors, and technology specialists—may contribute depending on the complexity of the trial.
The sponsor is responsible for ensuring that everyone involved in trial activities possesses the qualifications necessary to perform their assigned responsibilities competently.
Quality by Design
One of the most significant developments in ICH E6(R3) is the emphasis on Quality by Design (QbD). Instead of relying mainly on inspections after problems occur, quality should be incorporated into trial planning and conduct from the outset.
Sponsors should identify factors critical to trial quality before initiating the study. These critical factors include processes and data that directly affect participant safety and the reliability of trial results. Risk assessments should identify potential threats to these critical factors, allowing appropriate preventive measures to be implemented.
Quality management should remain continuous throughout the clinical trial. As new information becomes available, risks should be reassessed and quality management strategies updated accordingly.
Risk-Based Approach
The guideline promotes proportionate trial management based on risk. Trial procedures should correspond to the level of risk posed to participants and the importance of collected data. Low-risk studies should not be burdened with unnecessary procedures, while higher-risk trials require more comprehensive oversight.
Risk management includes identifying, evaluating, controlling, monitoring, and reviewing risks throughout the study lifecycle. Sponsors should particularly focus on risks affecting participant protection and the integrity of trial results. Operational complexity should be minimized whenever possible to improve trial efficiency and reduce burdens on investigators and participants.
Clinical Trial Protocol
The protocol serves as the foundation of every clinical trial. It should clearly describe the study objectives, design, methodology, statistical considerations, participant eligibility criteria, interventions, outcome measures, safety monitoring, and data management procedures.
A well-designed protocol helps ensure participant protection while generating reliable scientific evidence. Supporting documents such as statistical analysis plans, monitoring plans, and data management plans should also be clear, concise, and operationally feasible.
Responsibilities of Investigators
Investigators play a central role in conducting clinical trials according to GCP. They are responsible for protecting participants, following the approved protocol, obtaining informed consent, maintaining accurate records, reporting safety information promptly, and ensuring appropriate management of investigational products.
Investigators must possess adequate qualifications and sufficient resources to conduct the trial. They should communicate effectively with ethics committees, sponsors, and regulatory authorities whenever required. Any protocol deviations, serious adverse events, or unexpected safety concerns should be documented and reported according to regulatory requirements.
Responsibilities of Sponsors
Sponsors are responsible for designing, initiating, managing, financing, monitoring, and overseeing clinical trials. Although specific activities may be delegated to contract research organizations or other service providers, overall responsibility remains with the sponsor.
Key sponsor responsibilities include selecting qualified investigators, implementing quality management systems, ensuring appropriate monitoring, conducting audits when necessary, managing investigational products, maintaining trial documentation, analyzing data accurately, and reporting trial results.
Sponsors should establish systems for detecting noncompliance and implementing corrective and preventive actions whenever deficiencies are identified.
Data Governance and Computerized Systems
The updated guideline places significant emphasis on data governance throughout the entire data lifecycle. Data should remain accurate, complete, consistent, attributable, and traceable from initial collection through final analysis and long-term retention.
Electronic systems used in clinical research should be validated, secure, and appropriately maintained. Access controls, audit trails, user management, backup procedures, and system validation help preserve data integrity. Computerized systems should also include contingency plans for system failures to prevent data loss or disruption of trial activities.
The guideline acknowledges increasing use of digital technologies, wearable devices, sensors, and electronic data capture systems. These technologies should be selected and implemented appropriately according to participant characteristics and trial design.
Essential Documents and Record Keeping
Accurate documentation is fundamental to GCP compliance. Essential documents demonstrate that the trial has been conducted according to ethical, scientific, and regulatory requirements. Records should be maintained throughout the trial and retained according to applicable regulations after study completion.
The guideline includes appendices describing essential trial documents, investigator brochures, protocol contents, and record management requirements. Proper documentation facilitates inspections, audits, verification of trial conduct, and evaluation of data quality.
Innovation and Participant-Centered Research
ICH E6(R3) recognizes the increasing importance of innovation in clinical research. Modern clinical trials may use decentralized methods, remote monitoring, digital health technologies, electronic informed consent, and innovative trial designs.
The guideline also encourages engagement with patients, healthcare professionals, and patient advocacy groups during trial planning. Their perspectives can improve study feasibility, reduce unnecessary complexity, increase participant diversity, and generate more meaningful clinical outcomes.
Conclusion
The ICH E6(R3) Good Clinical Practice guideline provides a modern framework for conducting ethical, scientifically rigorous, and participant-centered clinical trials. While maintaining its traditional commitment to participant protection and reliable data, the revised guideline introduces greater flexibility through quality-by-design principles, risk-based management, modern technologies, and adaptive trial methodologies.
Reference:
International Council for Harmonisation (ICH). ICH Harmonised Guideline E6(R3): Guideline for Good Clinical Practice, Final Version, adopted 6 January 2025.
© 2025-2026 Law Justified Magazine, unless otherwise provided, all rights reserved.
The author(s) of each article published in the Law Justified Magazine is/are solely responsible for the content thereof; neither the Law Justified Magazine nor its editors or publisher nor anyone else involved in creating, producing, or distribution assumes any liability or responsibility for the accuracy, completeness, correctness or usefulness of any information provided in the Law Justified Magazine, nor shall they be liable for any direct, indirect, incidental, special, consequential or punitive damages arising out of the use of the Law Justified Magazine.
Disclaimer
Law Justified Magazine is fully open access, which means all its contents is freely available to its reader free of cost.
Publishes articles under CC BY-NC-ND 4.0 International Licence of creative commons licensing. That means, reusers can copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
Open Access Policy
About Law Justified Magazine
Law Justified Magazine is an open access, monthly, digital magazine, which publishes on legal issues majorly focusing on current legal developments for practitioners and professionals.
Frequency | Monthly
Mode | Online
Scope | Law
Language | English
Article Type | Short Article | Commentary
Starting Year of Publication | 2025